NBD-14189

CAS No. ——

NBD-14189( NBD14189 )

Catalog No. M17095 CAS No. ——

NBD-14189 (NBD14189) is a novel potent HIV-1 entry antagonist with potency as low as 63 nM against some clinical isolates.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    NBD-14189
  • Note
    Research use only, not for human use.
  • Brief Description
    NBD-14189 (NBD14189) is a novel potent HIV-1 entry antagonist with potency as low as 63 nM against some clinical isolates.
  • Description
    NBD-14189 (NBD14189) is a novel potent HIV-1 entry antagonist with potency as low as 63 nM against some clinical isolates, target HIV-1 gp120.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    NBD14189
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    428.406
  • Molecular Formula
    C18H16F4N4O2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    N-(2-amino-1-(4-(hydroxymethyl)thiazol-2-yl)ethyl)-5-(3-fluoro-4-(trifluoromethyl)phenyl)-1H-pyrrole-2-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Curreli F, et al. Eur J Med Chem. 2018 Jun 25;154:367-391.
molnova catalog
related products
  • IC-9564

    IC-9564 (AIDS033640) is a betulinic acid derivative and potent HIV entry inhibitor.

  • Tenofovir alafenamid...

    Tenofovir alafenamide fumarate (TAF) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV).

  • Escin IA;Aescin IA

    Escin IA is a triterpene saponin isolated from horse chestnut which inhibits HIV-1 protease with IC50 values of 35 μM. Escin IA has anti-TNBC metastasis activity and its action mechanisms involved inhibition of epithelial-mesenchymal transition process by down-regulating LOXL2 expression.